Search Results - "Ross Agner, Bue F."

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin by Vilsbøll, Tina, Blevins, Thomas C., Jodar, Esteban, Poulter, Neil, Tentolouris, Nikolaos, Ross Agner, Bue F., Lehmann, Lucine, Leiter, Lawrence A.

“…In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed‐ratio combination (IDegLira) versus comparators on cardiovascular…”
Get full text

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials by Komatsu, Mitsuhisa, Watada, Hirotaka, Kaneko, Shizuka, Ross Agner, Bue F, Nishida, Tomoyuki, Kaku, Kohei

“…Aims/Introduction To assess efficacy and safety of insulin degludec/liraglutide (IDegLira) in Japanese participants with type 2 diabetes across different…”
Get full text

DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs by Wang, Weiqing, Agner, Bue F. Ross, Luo, Bin, Liu, Lei, Liu, Ming, Peng, Yongde, Qu, Shen, Stachlewska, Karolina Amelia, Wang, Guixia, Yuan, Guoyue, Zhang, Qiu, Ning, Guang

“…Background DUAL I China, one of the DUAL trials, assessed efficacy/safety of insulin degludec/liraglutide (IDegLira) in Chinese adults with type 2 diabetes…”
Get full text

IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy by Watada, Hirotaka, Ross Agner, Bue F., Doshi, Ankur, Bardtrum, Lars, Ranthe, Mattis Flyvholm, Billings, Liana K.

“…Introduction DUAL II Japan (NCT02911948) was a 26-week, phase 3a randomized, treat-to-target trial which compared the efficacy and safety of IDegLira with…”
Get full text

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial by Billings, Liana K., Agner, Bue F. Ross, Altuntas, Yuksel, Grøn, Randi, Halladin, Natalie, Klonoff, David C., Tentolouris, Nikolaos, Jódar, Esteban

“…Background: Insulin degludec/liraglutide (IDegLira) results in glycated hemoglobin (HbA1c) levels comparable with basal-bolus (BB) therapy. Here, we assessed…”
Get full text

Assessment of left atrial volume and function in patients with permanent atrial fibrillation: comparison of cardiac magnetic resonance imaging, 320-slice multi-detector computed tomography, and transthoracic echocardiography by Agner, Bue F Ross, Kühl, Jørgen Tobias, Linde, Jesper James, Kofoed, Klaus F, Åkeson, Per, Rasmussen, Bo V, Jensen, Gorm B, Dixen, Ulrik

“…Atrial fibrillation (AF) is a common cardiac arrhythmia that is associated with substantial morbidity and mortality. AF is associated with enlargement of the…”
Get full text

DUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制 by Wang, Weiqing, Agner, Bue F. Ross, Luo, Bin, Liu, Lei, Liu, Ming, Peng, Yongde, Qu, Shen, Stachlewska, Karolina Amelia, Wang, Guixia, Yuan, Guoyue, Zhang, Qiu, Ning, Guang

“…摘要 背景 作为DUAL试验之一的DUAL I China评估了未口服抗糖药物(OADs)控制血糖的中国成人2型糖尿病(T2D)患者应用德谷胰岛素/利拉鲁肽(IDegLira)的有效性/安全性。 方法 这项3a期, 治疗导向的多中心随机对照试验中, 受试者糖化血红蛋白(HbA1c)为53.0‐85.8…”
Get full text

Left Ventricular Systolic Function Assessed by Global Longitudinal Strain is Impaired in Atrial Fibrillation Compared to Sinus Rhythm by Ross Agner, Bue F, Katz, Michael G, Williams, Zachary R, Dixen, Ulrik, Jensen, Gorm B, Schwarz, Karl Q

“…Atrial fibrillation (AF) is the most common aberrant cardiac arrhythmia. Many AF patients present with symptoms of dyspnea and fatigue, but have normal left…”
Get full text